CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 37.12 USD -5.43% Market Closed
Market Cap: 3.2B USD

Wall Street
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 82.79 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

Lowest
Price Target
32.32 USD
13% Downside
Average
Price Target
82.79 USD
123% Upside
Highest
Price Target
281.4 USD
658% Upside
CRISPR Therapeutics AG Competitors:
Price Targets
TGTX
TG Therapeutics Inc
22% Upside
SYRE
Spyre Therapeutics Inc
261% Upside
NTRA
Natera Inc
32% Upside
ANAB
AnaptysBio Inc
81% Upside
XGN
Exagen Inc
16% Upside
600201
Jinyu Bio-Technology Co Ltd
12% Upside
INCY
Incyte Corp
17% Upside
ACLX
Arcellx Inc
82% Upside

Revenue
Forecast

Revenue Estimate
CRISPR Therapeutics AG

For the last 8 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 28%. The projected CAGR for the next 3 years is 129%.

28%
Past Growth
129%
Estimated Growth
Estimates Accuracy
13%
Average Beat

Operating Income
Forecast

Operating Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CRSP's stock price target?
Price Target
82.79 USD

According to Wall Street analysts, the average 1-year price target for CRSP is 82.79 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

What is CRISPR Therapeutics AG's Revenue forecast?
Projected CAGR
129%

For the last 8 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 28%. The projected CAGR for the next 3 years is 129%.

Back to Top